- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00275067
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
A Phase I/II Trial of Arsenic Trioxide and Temozolomide in Combination With Radiation Therapy for Patients With Malignant Gliomas
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving arsenic trioxide and temozolomide together with radiation therapy after surgery may kill any remaining tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of arsenic trioxide and temozolomide when given together with radiation therapy and to see how well they work in treating patients with malignant glioma that has been removed by surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine the maximum tolerated dose (MTD) of arsenic trioxide and temozolomide when combined with radiotherapy in patients with resected supratentorial malignant glioma. (Phase I)
- Determine the toxicity of this regimen in these patients. (Phase I)
Secondary
- Determine the 6- and 12-month progression-free survival of patients treated with this regimen once an MTD is reached. (Phase II)
- Determine the radiographic response for patients treated with the above regimen. (Phase II)
- Determine the safety of this regimen in these patients. (Phase II)
OUTLINE: This is a phase I, dose-escalation study of arsenic trioxide and temozolomide followed by a phase II study.
- Phase I: Patients undergo radiotherapy once daily 5 days a week and receive oral temozolomide once daily for approximately 6½ weeks. Patients also receive arsenic trioxide IV over 1-4 hours once daily, 5 days a week in week 1 and then twice a week in weeks 2-7. Beginning within 3-5 weeks after completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 1 year in the absence of disease progression and unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of arsenic trioxide and temozolomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- Phase II: Patients undergo radiotherapy and receive arsenic trioxide and temozolomide as in phase I at the MTD. Patients then receive temozolomide as in phase I for up to 1 year in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 1 year.
PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for the phase I portion of this study. A total of 25 patients will be accrued for the phase II portion of this study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611-3013
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
-
Chicago, Illinois, United States, 60611-2998
- Hematology-Oncology Associates of Illinois
-
Naperville, Illinois, United States, 60540
- Edward Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed supratentorial malignant glioma of 1 of the following types:
- Glioblastoma multiforme
- Gliosarcoma
- Anaplastic astrocytoma
- Anaplastic oligodendroglioma
- Anaplastic mixed gliomas
- Anaplastic gliomas not otherwise specified
Has undergone surgical resection of tumor
- Patients with biopsy only are eligible
- Evaluable or measurable disease following resection of recurrent tumor is not mandated for entry into the study
- No brain metastases
PATIENT CHARACTERISTICS:
- Karnofsky performance status 60-100%
- Life expectancy > 3 months
- WBC > 3,000/mm^3
- Absolute neutrophil count > 2,000/mm^3
- Platelet count > 100,000/mm^3
- Hemoglobin > 10 g/dL (eligibility level for hemoglobin may be reached by transfusion)
- Creatinine ≤ 1.5 mg/dL
- Bilirubin ≤ 2 mg/dL
- Transaminases ≤ 2 times the upper limit of normal
- Serum potassium* > 4.0 mEq/dL
- Serum magnesium* > 1.8 mg/dL NOTE: *If these serum electrolytes are below the specified limits on the baseline laboratory tests, supplemental electrolytes should be administered to bring the serum concentrations to these levels before administering arsenic trioxide
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after completion of study treatment
- No second-degree heart block
- QT interval ≤ 460 msec
- No other malignancy within the past 3 years except curatively treated carcinoma in situ or basal cell carcinoma of the skin
- Patients who cannot undergo MRI are not eligible for this study
- No other serious concurrent infection or other medical illness that would jeopardize the ability of the patient to receive the therapy in this protocol with reasonable safety
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Patients must have recovered from the effects of surgery prior to the start of treatment (10-14 days minimum) and be maintained on a stable corticosteroid regimen for 5 days
- Concurrent glucocorticoid therapy allowed at the smallest effective dose
- Patients must be on non-enzyme-inducing anti-convulsants to minimize any drug reaction
- No prior radiation therapy, chemotherapy, immunotherapy, therapy with biologic agents (including immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumor-infiltrating lymphocytes, lymphokine-activated killer cells, or gene therapy), or hormonal therapy for their brain tumor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Radiation + temozolomide and arsenic trioxide
Radiation therapy followed by the combination of temozolomide and arsenic trioxide at the maximum tolerated dose determined in phase 1
|
Arsenic trioxide administered intravenously at a dose of 0.20mg/kg Daily x 5 week then twice per week
Other Names:
Temozolomide administered orally once per day 1 hour prior to radiation therapy at a dose of 75 mg/m2 x 42 days; at a dose of 200mg/m2 for 5 days every cycle (1 cycle = 28 days) after radiation therapy
Other Names:
All patients will receive 5940-6120 cGy of radiation therapy as 28-33 treatments/fractions (180-200 cGy/treatment) depending on whether they receive standard 3-D conformal radiation therapy or intensity modulated radiation therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose of arsenic trioxide and temozolomide in combination with radiotherapy
Time Frame: Toxicity evaluated prior to each treatment cycle
|
Escalating doses of study drug until dose limiting toxicities are observed.
|
Toxicity evaluated prior to each treatment cycle
|
Collect data on the toxicity of arsenic and temozolomide during radiation therapy
Time Frame: Toxicity evaluated prior to each treatment cycle
|
Toxicity of this drug combination during radiation therapy will be assessed.
|
Toxicity evaluated prior to each treatment cycle
|
Assess serum biomarkers and correlate with tumor tissue
Time Frame: At baseline, during radiation therapy, and prior to each cycle of chemotherapy
|
Blood will be drawn at baseline, during radiation therapy, and prior to each cycle of chemotherapy to assess serum biomarkers and correlate with tumor tissue.
|
At baseline, during radiation therapy, and prior to each cycle of chemotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine progression free survival at 6 and 12 months
Time Frame: At 6 and 12 months after beginning chemotherapy
|
Patients will undergo an MRI and neurological evaluation every 6 months while on chemotherapy.
|
At 6 and 12 months after beginning chemotherapy
|
Determine time to disease progression
Time Frame: At 6 and 12 months after beginning chemotherapy
|
Disease status will be assessed by MRI and neurological examination every 6 months until disease progression.
|
At 6 and 12 months after beginning chemotherapy
|
To determine overall survival
Time Frame: Every 6 months while on treatment
|
Survival status will be evaluated every 6 months while on treatment.
|
Every 6 months while on treatment
|
To determine radiographic response to study regimen
Time Frame: Every 6 months while on treatment
|
Radiographic response will be assessed by MRI every 6 months while on treatment
|
Every 6 months while on treatment
|
To collect safety data during the radiation therapy phase
Time Frame: Weekly during radiation therapy
|
EKG's will be done once per week and labs twice per week during radiation therapy phase to evaluate safety data.
|
Weekly during radiation therapy
|
To evaluate a potential surrogate marker for outcomes
Time Frame: At baseline, before and after radiation therapy, and every 2 cycles during chemotherapy
|
Blood will be drawn to analyze methylation patterns as a surrogate marker for outcomes at baseline, before and after radiation therapy, and every 2 cycles during chemotherapy.
|
At baseline, before and after radiation therapy, and every 2 cycles during chemotherapy
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Temozolomide
- Arsenic Trioxide
Other Study ID Numbers
- NU 04C1 (Other Identifier: Northwestern University)
- CDR0000456504 (Registry Identifier: PDQ)
- STU00007792 (Other Identifier: Northwestern University IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain and Central Nervous System Tumors
-
Children's Hospital Los AngelesUnknownBrain and Central Nervous System TumorsUnited States, Canada, Australia, Switzerland, New Zealand
-
Emory UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedVNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain TumorsBrain and Central Nervous System TumorsUnited States
-
St. Jude Children's Research HospitalCompletedBrain Tumors | Central Nervous System TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumors | Central Nervous System TumorsUnited States, Australia, Canada
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors
Clinical Trials on arsenic trioxide
-
Ruijin HospitalRecruitingRefractory Solid TumorsChina
-
CTI BioPharmaTerminatedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
National Cancer Institute (NCI)CompletedLymphoma | LeukemiaUnited States, Canada, Australia
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedLymphoma | Leukemia | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedTesticular Germ Cell Tumor | Extragonadal Germ Cell TumorUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
Northwestern UniversityNational Cancer Institute (NCI)TerminatedLymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Completed